Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate

MT Newswires Live

Jan 28, 2025

Allogene Therapeutics (ALLO) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.

The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.

The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.

Allogene shares were 0.3% lower in recent trading.

Price: 1.95, Change: +0.02, Percent Change: +0.78

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2506510250"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506510250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2506510250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-28 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506510250","market":"hk","top_or_hot":-1,"title":"Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ALLO) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.</p><p>The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.</p><p>The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.</p><p>Allogene shares were 0.3% lower in recent trading.</p><p>Price: 1.95, Change: +0.02, Percent Change: +0.78</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-28 23:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ALLO) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.</p><p>The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.</p><p>The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.</p><p>Allogene shares were 0.3% lower in recent trading.</p><p>Price: 1.95, Change: +0.02, Percent Change: +0.78</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLO","symbol_name":"Allogene Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2506510250","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506510250","pubTimestamp":1738079669,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Allogene Therapeutics  has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.Allogene shares were 0.3% lower in recent trading.Price: 1.95, Change: +0.02, Percent Change: +0.78","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALLO":"Allogene Therapeutics Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"Allogene Therapeutics获准开始ALLO-329候选药物的1期测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1},"content_text":"Allogene Therapeutics (ALLO) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.Allogene shares were 0.3% lower in recent trading.Price: 1.95, Change: +0.02, Percent Change: +0.78","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}